• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by KORU Medical Systems Inc. (Amendment)

    12/29/23 6:20:54 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care
    Get the next $KRMD alert in real time by email
    SC 13D/A 1 d692827dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 10)

     

     

    KORU Medical Systems, Inc.

    (Name of Issuer)

    Common Stock, Par Value $0.01 Per Share

    (Title of Class of Securities)

    759910102

    (CUSIP Number)

    JOSEPH M. MANKO, JR.

    HORTON CAPITAL PARTNERS, LLC

    1717 Arch Street, Suite 3740

    Philadelphia, PA 19103

    (215) 399 5402    

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 27, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

     

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 759910102

     

      1    

      NAMES OF REPORTING PERSONS:

     

      Horton Capital Partners Fund, LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

      (See Item 3)

     

      WC; OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

         7    

      SOLE VOTING POWER

     

         8  

      SHARED VOTING POWER

     

      7,609,751 (See Item 5)

         9  

      SOLE DISPOSITIVE POWER

     

       10  

      SHARED DISPOSITIVE POWER

     

      7,609,751 (See Item 5)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      7,609,751 (See Item 5)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      16.66% (See Item 5)

    14  

      TYPE OF REPORTING PERSON (See Instructions):

     

      PN


    CUSIP No. 759910102

     

      1    

      NAMES OF REPORTING PERSONS:

     

      Horton Freedom, LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

      (See Item 3)

     

      WC; OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

         7    

      SOLE VOTING POWER

     

         8  

      SHARED VOTING POWER

     

      453,231 (See Item 5)

         9  

      SOLE DISPOSITIVE POWER

     

       10  

      SHARED DISPOSITIVE POWER

     

      453,231 (See Item 5)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      453,231 (See Item 5)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.99% (See Item 5)

    14  

      TYPE OF REPORTING PERSON (See Instructions):

     

      PN


    CUSIP No. 759910102

     

      1    

      NAMES OF REPORTING PERSONS:

     

      Horton Capital Partners, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

      (See Item 3)

     

      WC; OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

         7    

      SOLE VOTING POWER

     

         8  

      SHARED VOTING POWER

     

      8,062,982 (See Item 5)

         9  

      SOLE DISPOSITIVE POWER

     

       10  

      SHARED DISPOSITIVE POWER

     

      8,062,982 (See Item 5)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      8,062,982 (See Item 5)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      17.66% (See Item 5)

    14  

      TYPE OF REPORTING PERSON (See Instructions):

     

      HC


    CUSIP No. 759910102

     

      1    

      NAMES OF REPORTING PERSONS:

     

      Horton Capital Management, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

      (See Item 3)

     

      WC; OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

         7    

      SOLE VOTING POWER

     

         8  

      SHARED VOTING POWER

     

      8,062,982 (See Item 5)

         9  

      SOLE DISPOSITIVE POWER

     

       10  

      SHARED DISPOSITIVE POWER

     

      8,062,982 (See Item 5)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      8,062,982 (See Item 5)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      17.66% (See Item 5)

    14  

      TYPE OF REPORTING PERSON (See Instructions):

     

      IA


    CUSIP No. 759910102

     

      1    

      NAMES OF REPORTING PERSONS:

     

      Joseph M. Manko, Jr.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

      (See Item 3)

     

      WC; OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

         7    

      SOLE VOTING POWER

     

      165,252

         8  

      SHARED VOTING POWER

     

      8,062,982 (See Item 5)

         9  

      SOLE DISPOSITIVE POWER

     

      165,252

       10  

      SHARED DISPOSITIVE POWER

     

      8,062,982 (See Item 5)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      8,228,234 (See Item 5)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      18.02% (See Item 5)

    14  

      TYPE OF REPORTING PERSON (See Instructions):

     

      IN


    Item 1. Security and Issuer.

    This statement relates to shares of common stock, par value $0.01 per share (“Common Stock”), of Koru Medical Systems, Inc., a New York corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 100 Corporate Drive, Mahwah, New Jersey.

    Horton Capital Partners Fund, LP, a Delaware limited partnership (“HCPF”), Horton Freedom, LP, a Delaware limited partnership (“Horton Freedom”), Horton Capital Partners LLC, a Delaware limited liability company (“HCP”), Horton Capital Management, LLC, a Delaware limited liability company (“HCM”), and Joseph M. Manko, Jr. (“Mr. Manko”) filed Schedule 13D with the Securities and Exchange Commission (the “SEC”) on May 23, 2017, as amended by Amendments Nos. 1 – 9 filed on December 4, 2017, December 21, 2017, March 16, 2018, September 20, 2018, December 21, 2018, January 29, 2020, August 20, 2020, April 6, 2021, and February 24, 2023 (“Schedule 13D”), to report their beneficial ownership of the shares of Common Stock of the Issuer. This Amendment No. 10 (“Amendment No. 10”) is filed with the SEC to amend and supplement Schedule 13D.

    Item 2. Identity and Background.

    (a) This statement is filed by HCPF, Horton Freedom, HCP, HCM, and Mr. Manko (Mr. Manko together with HCPF, Horton Freedom, HCP and HCM, the “Reporting Persons” and each a “Reporting Person”), with respect to shares of Common Stock of the Issuer.

    (b) The address of the principal office of each Reporting Person is 1717 Arch Street, Suite 3740, Philadelphia, PA 19103. The managing member of HCP and HCM is Mr. Joseph M. Manko, Jr.

    (c) The principal business of HCPF, Horton Freedom and HCP is purchasing, holding, and selling securities for investment purposes. The principal business of HCM is serving as the investment manager of HCPF and Horton Freedom. HCP is the general partner of HCPF and Horton Freedom. The principal occupation of Mr. Manko is serving as the managing member of HCM and HCP.

    (d) No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) Mr. Manko is a citizen of the United States of America.

    Item 3. Source and Amounts of Funds or other Consideration.

    The responses to Item 4 of this Amendment No. 10 are incorporated herein by reference. Unless otherwise disclosed below, the Reporting Persons used working capital to acquire shares of Common Stock.


    Item 4. Purpose of Transaction.

    The Reporting Persons acquired the shares of Common Stock for investment purposes. The purpose of this Amendment No. 10 is to disclose changes in the beneficial ownership of the shares of Common Stock held by the Reporting Persons including: (i) the issuance of shares of Common Stock to HCPF in consideration for Mr. Manko’s service as a director of the Issuer (the “Director Shares”); (iii) open market transactions in shares of Common Stock; (iv) that Horton Freedom agreed to sell shares of Common Stock to HCPF; and (iv) that Horton Freedom and HCP transferred shares of Common Stock to certain of their respective limited partners or members, including Mr. Manko.

    On March 31, 2023, 3,521 Director Shares were issued to HCPF; on June 30, 2023, 4,310 Director Shares were issued to HCPF; and on September 30, 2023, 5,484 Director Shares were issued to HCPF.

    HCPF acquired 20,000 shares of Common Stock in multiple open market purchases at prices ranging from: $2.49-2.59 on August 18, 2023, and $2.58-2.70 on August 21, 2023.

    On December 13, 2023, Horton Freedom agreed to sell 145,833 shares of Common Stock to HCPF in a private transaction at $2.40 per share.

    On December 27, 2023, Horton Freedom, in accordance with its terms, transferred 1,745,594 shares of Common Stock to certain of its limited partners, including HCP, for no consideration, representing a pro-rata distribution of such limited partners’ interests in Horton Freedom. HCP subsequently transferred 402,725 shares of Common Stock received from Horton Freedom to its members, including 165,252 shares of Common Stock to Mr. Manko.

    Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of shares of Common Stock at prices that would make the purchase or sale of such shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of shares of Common Stock on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.

    No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of the form of Schedule 13D, except as set forth herein, or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the shares of Common Stock of the Issuer, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in additional communications with management and the Board of the Issuer, engaging in discussions with stockholders of the Issuer and others about the Issuer and the Reporting Persons’ investment, making proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition) or operations of the Issuer, purchasing additional shares of Common Stock, selling some or all of their shares of Common Stock, or changing their intention with respect to any and all matters referred to in Item 4.

    Notwithstanding any of the foregoing, the Reporting Persons may at any time modify, change, abandon, or replace, some or all of the foregoing purposes and plans and discussions relating thereto or discontinue or re-continue such modifications, changes, abandonments, or replacements at any time.

     

    Item 5.

    Interest in Securities of the Issuer.

    (a)-(b) The percentages used herein are calculated based upon 45,669,362 shares of Common Stock issued and outstanding as of November 8, 2023, pursuant to the Quarterly Report on Form 10-Q filed by the Issuer with the SEC on November 8, 2023.


    As of the close of business on December 28, 2023:

    1. HCPF

    (a) Amount beneficially owned: 7,609,751*

    (b) Percent of class: 16.66%*

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 7,609,751*

    (iii) Sole power to dispose or direct the disposition: 0

    (iv) Shared power to dispose or direct the disposition: 7,609,751*

    (c) HCPF acquired 145,833 shares from Horton Freedom on December 13, 2023.

    2. Horton Freedom

    (a) Amount beneficially owned: 453,231*

    (b) Percent of class: 0.99*

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 453,231*

    (iii) Sole power to dispose or direct the disposition: 0

    (iv) Shared power to dispose or direct the disposition: 453,231*

    (c) Horton Freedom sold 145,833 shares to HCPF on December 13, 2023. Horton Freedom transferred 1,745,594 shares to certain of its limited partners on December 27, 2023.

    3. HCP

    (a) Amount beneficially owned: 8,062,982*

    (b) Percent of class: 17.66%*

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 8,062,982*

    (iii) Sole power to dispose or direct the disposition: 0

    (iv) Shared power to dispose or direct the disposition: 8,062,982*

    (c) HCP received and transferred 402,725 shares to its members on December 27, 2023.

    4. HCM

    (a) Amount beneficially owned: 8,062,982*

    (b) Percent of class: 17.66%*

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 8,062,982*

    (iii) Sole power to dispose or direct the disposition: 0

    (iv) Shared power to dispose or direct the disposition: 8,062,982*

    (c) HCM has not entered into any transactions in the securities of the Issuer during the past 60 days.

    5. Mr. Manko

    (a) Amount beneficially owned: 8,228,234*

    (b) Percent of class: 18.02%*

    (i) Sole power to vote or direct the vote: 165,252

    (ii) Shared power to vote or direct the vote: 8,062,982*

    (iii) Sole power to dispose or direct the disposition: 165,252

    (iv) Shared power to dispose or direct the disposition: 8,062,982*

    (c) Mr. Manko received 165,252 shares from HCP on December 27, 2023.


    * HCPF owns directly 7,609,751 shares of Common Stock. Horton Freedom owns directly 453,231 shares of Common Stock. HCM maintains discretionary investment and voting authority with respect to 7,609,751, and 453,231, shares of Common Stock held by HCPF and Horton Freedom, respectively. HCP may be deemed to be the beneficial owner of such shares of Common Stock because, in the event HCM’s investment advisory agreements with respect to such shares of Common Stock are terminated, HCP has the right to assume HCM’s discretionary investment and voting authority with respect to such shares of Common Stock. HCP is the general partner of HCPF and Horton Freedom. Mr. Manko owns directly 165,252 shares of Common Stock. Mr. Manko is the managing member of both HCM and HCP and may be deemed to be the beneficial owner of the shares of Common Stock held by HCPF and Horton Freedom. Each of HCM, HCP, and Mr. Manko disclaims beneficial ownership of the shares of Common Stock held by HCPF and Horton Freedom.

    (d) No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

    (e) Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Mr. Manko is a member of the Issuer’s Board of Directors.

    The Reporting Persons have entered into a Joint Filing Agreement, attached hereto as Exhibit 1, pursuant to which they have agreed to file this Amendment No. 10 jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

    The responses to Items 3, 4, and 5 of this Amendment No. 10 are incorporated herein by reference.

    Other than as described herein, there are no contracts, arrangements, understandings, or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit 1    Joint Filing Agreement, dated December 29, 2023.
    Exhibit 2    Securities Purchase Agreement dated, August 8, 2014, between the Issuer and HCPF and the Warrant, dated August 8, 2014, incorporated by reference to Exhibit 4.1 of the Issuer’s Annual Report on Form 10-K filed by the Issuer on May 8, 2015.
    Exhibit 3    Common Stock Purchase Agreement, dated as of December 17, 2018, by and among the Issuer, the Sellers named therein and the Purchasers named therein, incorporated by reference to Exhibit 10.1 of the Issuer’s Current Report on Form 8-K filed by the Issuer on December 17, 2018.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete, and correct.

     

    Dated: December 29, 2023     HORTON CAPITAL PARTNERS FUND, LP
       

    By: Horton Capital Partners, LLC,

    its General Partner

        By:  

    /s/ Joseph M. Manko, Jr.

        Name:   Joseph M. Manko, Jr.
        Title:   Managing Member
       

    HORTON FREEDOM, LP

       

    By: Horton Capital Partners, LLC,

    its General Partner

        By:  

    /s/ Joseph M. Manko, Jr.

        Name:   Joseph M. Manko, Jr.
        Title:   Managing Member
        HORTON CAPITAL PARTNERS, LLC
        By:  

    /s/ Joseph M. Manko, Jr.

        Name:   Joseph M. Manko, Jr.
        Title:   Managing Member
        HORTON CAPITAL MANAGEMENT, LLC
        By:  

    /s/ Joseph M. Manko, Jr.

        Name:   Joseph M. Manko, Jr.
        Title:   Managing Member
       

    /s/ Joseph M. Manko, Jr.

        JOSEPH M. MAN’KO, JR.

     

    Get the next $KRMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $KRMD

    DatePrice TargetRatingAnalyst
    2/14/2025$4.50Overweight → Neutral
    Piper Sandler
    7/25/2024$4.00Buy
    B. Riley Securities
    9/7/2023$4.00Buy
    Lake Street
    9/7/2023$4.50Buy
    B. Riley Securities
    11/10/2022$3.00 → $4.00Hold → Buy
    Canaccord Genuity
    11/10/2022$3.00 → $3.50Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $KRMD
    SEC Filings

    See more
    • KORU Medical Systems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - KORU Medical Systems, Inc. (0000704440) (Filer)

      5/15/25 4:56:41 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by KORU Medical Systems Inc.

      10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)

      5/7/25 4:22:04 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KORU Medical Systems, Inc. (0000704440) (Filer)

      5/7/25 4:21:14 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspe

      7/7/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025, according to a preliminary list of additions posted Friday, June 6, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by tot

      6/11/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th

      5/7/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cascella Robert was granted 4,189 shares, increasing direct ownership by 5% to 84,615 units (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      7/2/25 5:17:08 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Director Wholihan Edward was granted 4,189 shares, increasing direct ownership by 12% to 37,772 units (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      7/2/25 4:56:36 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Director Matin Shahriar was granted 4,189 shares, increasing direct ownership by 5% to 87,604 units (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      7/2/25 4:55:10 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • KORU Medical Systems downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded KORU Medical Systems from Overweight to Neutral and set a new price target of $4.50

      2/14/25 8:08:51 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on KORU Medical Systems with a new price target

      B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

      7/25/24 8:28:49 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on KORU Medical Systems with a new price target

      Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

      9/7/23 9:12:10 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Manko Joseph M. Jr. bought $349,999 worth of shares (145,833 units at $2.40) and sold $349,999 worth of shares (145,833 units at $2.40) (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      12/15/23 4:05:24 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Leadership Updates

    Live Leadership Updates

    See more
    • KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspe

      7/7/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025, according to a preliminary list of additions posted Friday, June 6, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by tot

      6/11/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio

      11/8/23 4:08:00 PM ET
      $BDX
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Financials

    Live finance-specific insights

    See more
    • KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th

      5/7/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems to Report First Quarter 2025 Financial Results on May 7, 2025

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2025 financial results on Wednesday, May 7, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international call

      4/16/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results With Record Revenues and Gross Profit; Issues Full Year 2025 Guidance

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. The Company also issued guidance for the full year 2025. Recent Highlights Fourth quarter 2024 net revenues of $8.8 million, a 23% increase over the prior year period; Full year 2024 net revenues of $33.6 million, an 18% increase over the prior year Fourth quarter 2024 Core business (Domestic and International) net revenues of $8.2 million, a

      3/12/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

      SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

      11/14/24 7:00:30 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

      SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

      11/13/24 4:23:54 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by KORU Medical Systems Inc.

      SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)

      5/23/24 7:00:28 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care